JP Morgan Maintains Overweight on RxSight, Lowers Price Target to $20
JP Morgan analyst Robbie Marcus maintains RxSight (NASDAQ:RXST) with a Overweight and lowers the price target from $22 to $20.
Needham Reiterates Buy on RxSight, Maintains $22 Price Target
Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $22 price target.
RxSight Sees FY23 Revenue $78M-$83M Vs $76.7M Est
2023 Guidance Highlights
Provided 2023 revenue guidance range of $78.0 million to $83.0 million, representing implied growth of 59% to 69% compared to
Earnings Scheduled For March 6, 2023
Companies Reporting Before The Bell
• Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.
Rxsight Raised $50M Via Secondary Equity Offering For Commercial And Marketing Expansion, Funding Of Product Development, Research And Clinical Development
RxSight, Inc. ("RxSight"), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced today that it has priced its underwritten public offering.
Needham Reiterates Buy on RxSight, Maintains $22 Price Target
Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $22 price target.
Benzinga’s Top Ratings Upgrades, Downgrades For December 12, 2022
Upgrades For Colliers International Group Inc (NASDAQ:CIGI), Goldman Sachs upgraded the previous rating of Neutral to Buy. Colliers…
RxSight Earnings Perspective: Return On Capital Employed
Benzinga Pro data, RxSight (NASDAQ:RXST) reported Q3 sales of $12.62 million. Earnings fell to a loss of $16.82…
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
Needham Maintains Buy on RxSight, Raises Price Target to $22
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and raises the price target from $19 to $22.